Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
disease save search
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Published: 2024-04-16 (Just crawled : 11:00) - globenewswire.com
CGEM | $16.55 -0.72% -0.91% 160K
|
| Email alert
Add to watchlist
expansion therapeutics
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $376.26 -0.47% -0.43% 180K
|
Health Technology
| Email alert
Add to watchlist
disease vyvgart for
MRI Systems Market size is set to grow by USD 2.49 billion from 2023-2027, increasing prevalence of diseases coupled with growing geriatric population boost the market, Technavio
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
RYLPF | $20.515 0.06% 3.85% 86
|
Health Technology
| Email alert
Add to watchlist
CAJPY | $28.92 -0.17% -0.41% 24K
|
n/a
| Email alert
Add to watchlist
CAJFF | $28.732 1.12% -28.15% 0
|
Electronic Technology
| Email alert
Add to watchlist
growing set market
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.785 -0.31% -0.21% 240K
|
n/a
| Email alert
Add to watchlist
disease treatment for meeting therapeutics
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
|
| O: 41.42%
H: 42.68%
C: 22.59%
conference disease association alzheimer’s presentation international research for trial
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI M | $4.95 -1.98% -2.23% 530K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
LH | $203.32 -1.17% 0.0% 670K
|
Health Services
|
| O: 0.82%
H: 0.0%
C: 0.0%
test blood for neurodegenerative labcorp
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
Published: 2024-04-11 (Crawled : 20:00) - globenewswire.com
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
| Email alert
Add to watchlist
pax-101 update key potential milestone submission trypanosoma africa tropical disease
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Published: 2024-04-11 (Crawled : 17:00) - biospace.com/
KPRX | $0.56 -2.58% 0.03% 46K
|
Manufacturing
|
| O: 3.23%
H: 0.16%
C: -1.79%
granted approval pharmaceuticals research for grant trial foundation study
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
IPSC | $3.67 -6.14% -6.39% 42K
|
Professional, Scientific, and T...
|
| O: 3.39%
H: 11.53%
C: 2.02%
disease million pipeline acquisition expansion therapeutics
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 11:00) - prnewswire.com
EVGN | $0.6863 -11.33% -13.64% 120K
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
conference disease meeting week
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.06 -15.57% -19.32% 370K
|
Health Technology
|
| O: 4.9%
H: 6.03%
C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Published: 2024-04-10 (Crawled : 20:00) - globenewswire.com
CLLS | $2.61 -2.97% -3.86% 42K
|
Health Technology
|
| O: 0.72%
H: 1.6%
C: -0.36%
metabolic treatment for
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
SILO | $1.9 -3.55% -2.07% 31K
|
Finance and Insurance
|
| O: -0.46%
H: 2.75%
C: -3.67%
pharma disease alzheimer’s acquire spc-14
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
SCYX | $1.47 1.73% 0.34% 130K
|
Health Technology
|
| O: -1.84%
H: 1.87%
C: -1.25%
scy-247 congress preclinical
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.71 3.01% 2.35% 1.5M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
CRL | $235.93 -2.24% 0.0% 460K
|
Commercial Services
|
| O: 0.93%
H: 0.36%
C: -0.05%
rare disease collaboration therapeutics therapy
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
Published: 2024-04-09 (Crawled : 12:30) - neurosense.investorroom.com
NRSN 4 d | $1.53 -4.38% -3.23% 73K
|
|
| O: 8.14%
H: 3.71%
C: -7.53%
disease order diagnostics neurodegenerative
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
NAMS | $19.74 0.2% 0.28% 270K
|
n/a
|
| O: -6.3%
H: 2.72%
C: -2.67%
pharma disease global trial cardiovascular
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.